169 related articles for article (PubMed ID: 10408864)
21. The prognostic value of BCAR1 in patients with primary breast cancer.
Dorssers LC; Grebenchtchikov N; Brinkman A; Look MP; van Broekhoven SP; de Jong D; Peters HA; Portengen H; Meijer-van Gelder ME; Klijn JG; van Tienoven DT; Geurts-Moespot A; Span PN; Foekens JA; Sweep FC
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6194-202. PubMed ID: 15448007
[TBL] [Abstract][Full Text] [Related]
22. [Expression and significance of urokinase-type plasminogen activator in breast cancer].
Xiao J; Zhang G; Xia W
Zhonghua Zhong Liu Za Zhi; 1999 May; 21(3):196-8. PubMed ID: 11776834
[TBL] [Abstract][Full Text] [Related]
23. Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer.
Harbeck N; Kates RE; Gauger K; Willems A; Kiechle M; Magdolen V; Schmitt M
Thromb Haemost; 2004 Mar; 91(3):450-6. PubMed ID: 14983219
[TBL] [Abstract][Full Text] [Related]
24. Multimarker phenotype predicts adverse survival in patients with lymph node-negative colorectal cancer.
Zlobec I; Minoo P; Baumhoer D; Baker K; Terracciano L; Jass JR; Lugli A
Cancer; 2008 Feb; 112(3):495-502. PubMed ID: 18076013
[TBL] [Abstract][Full Text] [Related]
25. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
Yu H; Levesque MA; Clark GM; Diamandis EP
Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of TP53 protein accumulation in human primary breast cancer: an analysis by luminometric immunoassay on 1491 tumor cytosols.
Berns EM; De Witte HH; Klijn JG; Willman K; Look MP; Meijer-Van Gelder ME; Benraad TJ; Foekens JA
Anticancer Res; 1997; 17(4B):3003-6. PubMed ID: 9329586
[TBL] [Abstract][Full Text] [Related]
27. Which cyclin E prevails as prognostic marker for breast cancer? Results from a retrospective study involving 635 lymph node-negative breast cancer patients.
Sieuwerts AM; Look MP; Meijer-van Gelder ME; Timmermans M; Trapman AM; Garcia RR; Arnold M; Goedheer AJ; de Weerd V; Portengen H; Klijn JG; Foekens JA
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3319-28. PubMed ID: 16740753
[TBL] [Abstract][Full Text] [Related]
28. Urokinase-type plasminogen activator and plasminogen-activator-inhibitor type 1 predict metastases in good prognosis breast cancer patients.
De Cremoux P; Grandin L; Diéras V; Savignoni A; Degeorges A; Salmon R; Bollet MA; Reyal F; Sigal-Zafrani B; Vincent-Salomon A; Sastre-Garau X; Magdelénat H; Mignot L; Fourquet A;
Anticancer Res; 2009 May; 29(5):1475-82. PubMed ID: 19443353
[TBL] [Abstract][Full Text] [Related]
29. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients.
Korkolis DP; Tsoli E; Fouskakis D; Yiotis J; Koullias GJ; Giannopoulos D; Papalambros E; Nikiteas NI; Spiliopoulou CA; Patsouris E; Asimacopoulos P; Gorgoulis VG
Anticancer Res; 2004; 24(3b):2061-8. PubMed ID: 15274401
[TBL] [Abstract][Full Text] [Related]
30. The complex between urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-I) independently predicts response to first-line endocrine therapy in advanced breast cancer.
Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot AJ; van Tienoven DT; Beex LV; Sweep FC
Thromb Haemost; 2004 Mar; 91(3):514-21. PubMed ID: 14983227
[TBL] [Abstract][Full Text] [Related]
31. Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor.
Chang J; Clark GM; Allred DC; Mohsin S; Chamness G; Elledge RM
Cancer; 2003 Feb; 97(3):545-53. PubMed ID: 12548595
[TBL] [Abstract][Full Text] [Related]
32. Urokinase-plasminogen activator in breast cancer: assay by both catalytic and immunoassay.
Reilly D; Andreasen PA; Duffy MJ
Blood Coagul Fibrinolysis; 1991 Feb; 2(1):47-50. PubMed ID: 1772998
[TBL] [Abstract][Full Text] [Related]
33. Expression of high p53 levels in colorectal cancer: a favourable prognostic factor.
Adrover E; Maestro ML; Sanz-Casla MT; del Barco V; Cerdán J; Fernández C; Balibrea JL
Br J Cancer; 1999 Sep; 81(1):122-6. PubMed ID: 10487622
[TBL] [Abstract][Full Text] [Related]
34. Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumor tissue from patients with primary breast cancer.
Riisbro R; Christensen IJ; Piironen T; Greenall M; Larsen B; Stephens RW; Han C; Høyer-Hansen G; Smith K; Brünner N; Harris AL
Clin Cancer Res; 2002 May; 8(5):1132-41. PubMed ID: 12006529
[TBL] [Abstract][Full Text] [Related]
35. Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients.
Kröger N; Milde-Langosch K; Riethdorf S; Schmoor C; Schumacher M; Zander AR; Löning T
Clin Cancer Res; 2006 Jan; 12(1):159-68. PubMed ID: 16397038
[TBL] [Abstract][Full Text] [Related]
36. Expression of p53 protein has no independent prognostic value in breast cancer.
Pietiläinen T; Lipponen P; Aaltomaa S; Eskelinen M; Kosma VM; Syrjänen K
J Pathol; 1995 Nov; 177(3):225-32. PubMed ID: 8551383
[TBL] [Abstract][Full Text] [Related]
37. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
[TBL] [Abstract][Full Text] [Related]
38. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
Fox SB; Taylor M; Grøndahl-Hansen J; Kakolyris S; Gatter KC; Harris AL
J Pathol; 2001 Sep; 195(2):236-43. PubMed ID: 11592104
[TBL] [Abstract][Full Text] [Related]
39. Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer.
Tecimer C; Doering DL; Goldsmith LJ; Meyer JS; Abdulhay G; Wittliff JL
Gynecol Oncol; 2001 Jan; 80(1):48-55. PubMed ID: 11136569
[TBL] [Abstract][Full Text] [Related]
40. Nonlinear discriminant analysis and prognostic factor classification in node-negative primary breast cancer using probabilistic neural networks.
Le Goff JM; Lavayssière L; Rouëssé J; Spyratos F
Anticancer Res; 2000; 20(3B):2213-8. PubMed ID: 10928180
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
